Welcome to our first issue of touchREVIEWS in RMD. This free-to-access issue is full of topical content addressing the most important and salient developments in the management of rheumatic and musculoskeletal disorders, which we think will be of interest for you, including articles around systemic lupus erythematosus, ANCA associated vasculitis, rheumatoid arthritis and much more.
We hope you’ll find something of interest in this issue, and we look forward to continuing to share new and exciting content into 2022 and beyond. Thanks to all who contributed and provided their expertise in putting together this edition, and to all of our authors, editorial board members and partners for their work towards our first journal issue. If you’re interested in contributing to our upcoming issues, please feel free to submit [here] or contact us directly.
Foreword – touchREVIEWS in RMD Vol 1 Issue 1 – 2022
Welcome to our first issue of touchREVIEWS in RMD. This free-to-access issue is full of topical content addressing the most important and salient developments in the management of rheumatic and musculoskeletal disorders, which we think will be of interest to you, including articles around systemic lupus erythematosus (SLE), antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, rheumatoid arthritis (RA) […]
Letter from the Editor-in-Chief
Letter from the Editor-in-Chief
Dear readers I am delighted to take on the mantle of Editor-in-Chief for touchREVIEWS in RMD and am grateful to have this opportunity to share some details of my background and my passion for great medical education with you. My first job after leaving school was to work (very briefly) for an estate agent in […]
The Links Between Fibromyalgia, Hypermobility and Neurodivergence
Fibromyalgia (FM) is defined as widespread musculoskeletal pain and tenderness, in the absence of another explanation. Poor sleep, fatigue and pain are all associated with FM. Diagnostic criteria are well defined,1 and the prevalence of FM appears to be steadily increasing, with patients presenting at progressively younger ages. Experience suggests that most patients are female, and […]
Janus Kinase Inhibitor Selectivity in Rheumatoid Arthritis: Where Do We Stand?
Targeting the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway with JAK inhibitors (JAKis) has opened multiple avenues for the treatment of rheumatoid arthritis (RA) and, more generally, chronic inflammatory diseases. The JAK family comprises JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2).1 Although structurally similar, these four members display subtle differences in the […]
The Role of Self-management in Inflammatory Arthritis
Living with inflammatory arthritis (IA) can pose multiple challenges throughout the lives of patients, as well as to their families and friends. Despite major advances in available treatments for inflammatory arthritides, such as rheumatoid arthritis and spondyloarthritis, there remains an important role for the person living with IA. In this regard, an important aspect of […]
Comprehensive Review Exploring Novel Treatments for Psoriatic Arthritis and Axial Spondyloarthritis from 2016 to 2021
The seronegative spondyloarthritides are a group of inflammatory arthropathies that are related in aspects of their clinical and radiographic presentations and genetic predisposition. Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are two of the major diseases classified under this umbrella, in addition to reactive arthritis, inflammatory bowel disease-associated arthritis and undifferentiated spondyloarthritis. PsA is an […]
The Role of Interleukin-23 Inhibition in the Treatment of Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease with an estimated global prevalence of 0.2%.1,2 The condition may occur in up to 30% of patients with psoriasis, with PsA typically developing 10 years after the onset of skin disease.1,3,4 PsA is a highly heterogeneous disease, with manifestations including peripheral arthritis, axial disease, psoriasis, nail changes, dactylitis and enthesitis, […]
Avacopan: An Oral Complement 5a Inhibitor for ANCA-associated Vasculitis
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) includes several distinct clinical entities: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and renal-limited vasculitis. What all these diseases have in common is the presence of serum autoantibodies, designated as ANCA, that react with antigens in the cytoplasm of neutrophilic granulocytes and monocytes.1,2 The […]
Anifrolumab: An Inhibitor of Type I Interferon for the Treatment of Patients with Systemic Lupus Erythematosus
Isaacs and Lindenmann first identified interferons (IFNs) in 1957.1 They discovered that chicken embryo chorioallantois membranes pre-treated with heat-inactivated influenza virus inhibited the growth of live influenza virus, and thus, the abridged term for ‘viral interference’ became ‘interferon’. A little over 20 years later, there was speculation that not only did IFNs offer protection against viral […]
Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Systemic lupus erythematosus (SLE) is a typical systemic autoimmune disease that commonly affects women in their 20s and 30s, with a male-to-female ratio of 1:9–1:10.1–5 The disease affects multiple organs in the body, including the skin, joints, kidneys, serosa, lungs, central nervous system and blood vessels, as well as the haematopoietic system, thereby presenting various clinical […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!